Antibiotics

Biography

Biography: John M. Clerici

Abstract

Biotechnology companies are increasingly seeking to use non-dilutive capital from the U.S. Government, foreign governments, and non-governmental organizations as part of their commercialization objectives. Companies must have a full understanding of funding and procurement opportunities and help communicate the advantages and the state of development of its technology so that it resonates most effectively with funding and purchasing decision-makers. Private equity and venture capital firms are increasingly aware of the fact that legislation and policies established in the US and the EU directly influence the value of their investments. It is critical for companies undertake an effort in identifying and analyzing global government procurement trends as well as assessing the risks associated with investing in companies that receive U.S. federal and state funding and government contracts. In the specific area of emerging disease and engineered threats , including antibiotics, this approach is more important than any other area of biotechnology given the risks of development and the pricing pressure on new drugs, as well as the limited market for many of these products. Thus, access to non-dilutive capital becomes critical. This talk will explore the sources of such capital, the experience of past applicants (both successful and unsuccessful) and prospects for future funding in this age of government austerity.